Skip to main content
Premium Trial:

Request an Annual Quote

Between the Coasts

A small biotech firm based in Iowa is getting noticed for its research on cancer and Ebola, the Wall Street Journal reports.

Charles Link started NewLink Genetics in 1999 by spinning out immunotherapy technology developed at Iowa Methodist Medical Center in Des Moines and has raised funds for it from Stine Seed Farm's Harry Stine. NewLink Genetics' focus on cancer immunotherapy has garnered interest from Roche's Genentech, which has led to a $150 million deal, the Journal notes.

The company's Ebola vaccine research started as a side project, but got thrust into the limelight with the outbreak in Africa. Merck licensed its experimental vaccine, which is now undergoing clinical trial testing in West Africa, for $30 million, the WSJ notes.

But, the Journal wonders whether NewLink will still be able to attract talent to Iowa The company has, it adds, opened sites in Austin for sales people and outside Boston for its Ebola work.

"Building an early-stage biotech company is a really hard thing," says Peter Barrett from Cambridge-based Atlas Ventures. "Trying to get very specialized people in a remote area may be very difficult."

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.